



NCCN Trends™ is a new tool from the National Comprehensive Cancer Network that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the February 2009 NCCN Trends survey.


Question 1: Which of the following best describes your role in the management of cancer patients?




Question 2: In a patient with stage IV clear cell carcinoma of the kidney, which first-line therapy do you prefer? (Results filtered to include only practicing physicians in medical oncology/hematology who treat kidney cancer patients)




Question 3: For the same patient as described above (stage IV clear cell kidney cancer) and based on your answer to the first question, which would be your choice of subsequent therapy after progression? (Results filtered to include only practicing physicians in medical oncology/hematology who treat kidney cancer and who also answered “sunitinib” for Question 2)




Question 4: Do you routinely order KRAS mutation status prior to initiating initial chemotherapy for metastatic colon cancer? (Results filtered to include only practicing physicians in medical oncology/hematology who treat colon cancer)



Question 5: For a good performance status patient with metastatic colorectal cancer and with KRAS wild type (WT), what is your preferred first-line treatment option? (Results filtered to include only practicing physicians in medical oncology/hematology who treat colorectal cancer)



Question 6: In chronic myelogenous leukemia (CML) patients who have progressed on imatinib, which is your preferred choice for second line therapy? (Results filtered to include only practicing physicians in medical oncology/hematology who treat CML)





NCCN Trends™ is a new tool from the National Comprehensive Cancer Network that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission a **NCCN Trends™** survey, or to discuss analytic and data services, please contact:

Jennifer M. Hinkel
Manager, Business Insights
215-690-0250
hinkel@nccn.org

For information on other NCCN programs and resources, please contact:

C. Lyn Fitzgerald
Director, Pharma/Biotech
215-690-0226
fitzgerald@nccn.org

National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

*All NCCN Trends™ survey content and resulting data is owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes.



National
Comprehensive
Cancer
Network®

275 Commerce Drive • Suite 300
Fort Washington, PA
Telephone: 215-690-0300
Fax: 215-690-0280



www.nccn.org